TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients
Pernille Bræmer Hertel, Dongsheng Tu, Bent Laursen Ejlertsen, Maj-Britt Raaby Jensen, Eva Balslev, Shan Jiang, Frances P. O'Malley, Kathleen I. Pritchard, Lois E. Shepherd, Annette Bartels, Nils Brunner, Torsten O. Nielsen
Dive into the research topics of 'TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients'. Together they form a unique fingerprint.